| Assessment Status |
Assessment Process Complete |
| HTA ID |
- |
| Drug |
Ponatinib |
| Brand |
Iclusig® |
| Indication |
Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. |
| Rapid review commissioned |
02/10/2013 |
| Rapid review completed |
01/12/2013 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant |
01/07/2015 |
| NCPE assessment completed |
05/01/2016 |
| NCPE assessment outcome |
Reimbursement not Recommended |
